Questions to answer below:
Why is it imperative to write your NPI and DEA # on this script?
Why will you check the prescription monitoring program in your state prior to prescribing?
What factors influence the prescribing of an extended release stimulant formulation over an immediate release formulation in the treatment of ADHD and what empirical evidence supports the efficacy and benefits of this choice?
Please answer all the questions above. And provide 2 7th edition APA scholarly references within 5 years. I have provided one reference below
Stahl, S.M. (2021).
Stahl’s essential psychopharmacology: Prescribers guide (7th ed.). Cambridge University Press. ISBN: 9781108926010